Skip to content
PubMed This is a summary of 8 peer-reviewed journal articles Updated
Pediatric Hematology

Long-Term Monitoring and Surveillance

At a Glance

For children with SAMD9L-associated disease, regular follow-up tailored to their current health is essential. Blood counts, bone marrow and genetic tests, and checks of movement, vision, and development help the care team spot recovery or concerning changes early.

Living with SAMD9L-associated disease requires a shift in perspective. Rather than a one-time “fix,” management is a long-term commitment to longitudinal surveillance—the practice of tracking your child’s health markers over months and years to catch changes early [1][2]. Because the “genetic landscape” of your child’s bone marrow can shift, these regular check-ups are the most powerful tool your care team has to distinguish between a body that is experiencing beneficial somatic clonal rescue and one that may be heading toward a more serious condition [3][1].

The Surveillance Roadmap

There is no single “one-size-fits-all” schedule for SAMD9L monitoring. Instead, your hematologist will create a risk-adapted schedule based on your child’s current blood counts, age, phenotype, and previous marrow results [1][2].

  • Complete Blood Counts (CBC): These monitor for cytopenias (low counts) or neutropenia (low infection-fighting cells). The frequency is heavily adapted to current trends [4][2].
  • Bone Marrow Aspirate and Biopsy: This procedure allows doctors to look directly at the “blood factory.” They check for cellularity (how many cells are growing), dysplasia (if cells look abnormal), and the percentage of “blast” cells (immature cells that could signal leukemia) [3][2].
  • Cytogenetics and FISH: These specialized tests track monosomy 7 (a missing chromosome 7). Doctors look for trends: a declining clone size is often a sign of recovery, while a growing or persistent clone may indicate a higher risk for Myelodysplastic Syndrome (MDS) [2][1].
  • Next-Generation Sequencing (NGS): This “deep dive” into the DNA looks for new somatic mutations (changes that happen after birth). Some mutations, like RUNX1 or EZH2, are closely monitored. Their significance depends heavily on variant burden and expert hematopathology review; they are not automatic transplant triggers [2][3].

Neurologic and Physical Monitoring

Because SAMD9L can affect the brain’s balance center, your child’s coordination and development need their own tracking system [5][4].

  • Standardized Motor Testing: Your child may have evaluations using formal tests to measure balance, fine motor skills, and eye movements (nystagmus) [5].
  • Ophthalmic Screening: Some children may develop subtle eye or retinal changes. Periodic exams by a pediatric ophthalmologist can ensure vision is protected based on specific symptoms [4][6].
  • Developmental Milestones: Monitoring for developmental regression (losing skills your child already had) is just as important as tracking blood counts. Mention any new clumsiness or school difficulties to your care team immediately [7][5].

Managing the Psychological Burden

The term “scanxiety”—the intense anxiety that builds before a medical test or result—is a very real experience for parents of children with rare diseases. The cycle of waiting for a bone marrow report or a CBC result can be emotionally draining [8].

  • Focus on Trends, but Respond to Acute Events: While doctors look for the “story” the data tells over several months, one critically low blood count, fever, bleeding symptom, or rapid neurologic change cannot be dismissed because prior results were reassuring. Always pair trend-based monitoring with an explicit same-day fever/symptom threshold [1][3].
  • Advocate for Support: Many specialist centers have “Child Life” specialists or pediatric psychologists who can help your child feel empowered during procedures. Don’t hesitate to ask for these resources for yourself as well [8].
  • Active Risk-Adapted Monitoring: Knowing that your child is under the explicit surveillance of regular monitoring can sometimes provide its own kind of peace [2][1].

Common questions in this guide

How often should my child have blood counts and bone marrow tests for SAMD9L disease?
There is no single schedule for every child. A hematologist sets the plan based on blood counts, age, clinical features, and earlier marrow results, then adjusts it when trends change.
What do monosomy 7 and UPD7q results mean in SAMD9L disease?
These chromosome findings are followed over time in bone marrow cells. A shrinking group of abnormal cells or evidence of UPD7q may fit with beneficial rescue, while a growing or persistent monosomy 7 change may indicate higher risk for myelodysplastic syndrome; expert review is needed, and this result alone does not automatically mean a transplant is needed.
Why are RUNX1 and EZH2 checked on my child's genetic testing?
RUNX1 and EZH2 are somatic mutations, meaning changes that occur after birth in some cells. Their significance depends on how much of the change is present and how an expert hematopathologist interprets the full result; finding one does not automatically mean a transplant is needed.
Which movement, vision, or development changes should I report?
Tell the care team about new clumsiness, balance problems, unusual eye movements such as nystagmus, vision concerns, school difficulties, or loss of skills your child previously had. A rapid neurologic change should be reported promptly rather than waiting for the next routine visit.
When should I call the doctor between surveillance visits?
Follow the same-day instructions from your child's care team for fever, bleeding, a critically low blood count, or a rapid neurologic change. These problems should not be dismissed because earlier tests were reassuring.
What support can help my child cope with repeated tests and procedures?
Ask whether your center offers Child Life services or a pediatric psychologist. These professionals can help children prepare for blood draws and marrow procedures, and they may also connect parents with support for anxiety around testing and results.

Get notified when new evidence is published on SAMD9L-associated autoinflammatory syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (8)
  1. 1

    Genetic and clinical spectrum of SAMD9 and SAMD9L syndromes: from variant interpretation to patient management.

    Sahoo SS, Erlacher M, Wlodarski MW

    Blood 2025; (145(5)):475-485 doi:10.1182/blood.2022017717.

    PMID: 39475954
  2. 2

    Spontaneous remission and loss of monosomy 7: a window of opportunity for young children with SAMD9L syndrome.

    Erlacher M, Andresen F, Sukova M, et al.

    Haematologica 2024; (109(2)):422-430 doi:10.3324/haematol.2023.283591.

    PMID: 37584291
  3. 3

    Constitutional SAMD9L mutations cause familial myelodysplastic syndrome and transient monosomy 7.

    Pastor VB, Sahoo SS, Boklan J, et al.

    Haematologica 2018; (103(3)):427-437 doi:10.3324/haematol.2017.180778.

    PMID: 29217778
  4. 4

    Ataxia-pancytopenia syndrome with SAMD9L mutations.

    Gorcenco S, Komulainen-Ebrahim J, Nordborg K, et al.

    Neurology. Genetics 2017; (3(5)):e183 doi:10.1212/NXG.0000000000000183.

    PMID: 28852709
  5. 5

    Assessing Long-Term Neurologic Outcomes in SAMD9L-Related Ataxia-Pancytopenia Syndrome.

    Zingariello CD, Chen DH, Raskind WH, et al.

    Movement disorders clinical practice 2024; (11(6)):728-733 doi:10.1002/mdc3.14038.

    PMID: 38594844
  6. 6

    Ataxia pancytopenia syndrome due to SAMD9L mutation presenting as demyelinating neuropathy.

    Vaughan D, Bogdanova-Mihaylova P, Costello DJ, et al.

    Journal of the peripheral nervous system : JPNS 2020; (25(4)):433-437 doi:10.1111/jns.12409.

    PMID: 32808377
  7. 7

    Successful Haploidentical Bone Marrow Transplantation of an Infant With a Novel Mutation in SAMD9L Gene (Ataxia-Pancytopenia Syndrome).

    Alicea Marrero MM, Español M, Marrero-Rivera G, et al.

    Journal of pediatric hematology/oncology 2022; (44(7)):419-420 doi:10.1097/MPH.0000000000002537.

    PMID: 36054901
  8. 8

    Aplastic Anemia and MDS International Foundation (AAMDSIF): Bone marrow failure disease scientific symposium 2016.

    Zeidan AM, Battiwalla M, Berlyne D, Winkler T

    Leukemia research 2017; (53()):8-12 doi:10.1016/j.leukres.2016.11.011.

    PMID: 27923195

This page explains long-term monitoring for children with SAMD9L-associated disease for informational purposes only and does not replace medical advice. Your child's hematology team should set testing schedules and advise you about urgent symptoms.